Citigroup’s ProShares Ultra CRCL CRCA Stock Holding History

Citigroup’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$271K	Buy	15,560 +8,746	+128%	+$153K	﹤0.01%	4075
2026 Q2	$87.3K	Buy	+6,814	New	+$263K	﹤0.01%	4760

Other funds holding CRCA

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Hollencrest Capital Management Newport Beach, California $1.56B AUM 20.98% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Citigroup's CRCA Position: Q3 2026 in Review

Citigroup increased its ProShares Ultra CRCL (CRCA) stake by 128% in Q3 2026, buying an estimated $153K and bringing the position to 15,560 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #4075.

Citigroup first reported a position in CRCA in Q2 2026 and has held it in 2 quarters since. 6 funds tracked by Wall St. Rank hold CRCA as of Q3 2026.

Citigroup held 15,560 shares of ProShares Ultra CRCL worth $271K as of Q3 2026.
Citigroup bought 8,746 ProShares Ultra CRCL shares in Q3 2026, an estimated $153K.
ProShares Ultra CRCL made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4075 holding.
Citigroup first reported a position in ProShares Ultra CRCL in Q2 2026 and has held it in 2 quarters since.
6 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.